How Much Does Evenity (Romosozumab) Cost in Arkansas in 2026?

Evenity List Price and Cash-Pay Cost in Arkansas

The wholesale acquisition cost (WAC) for Evenity sits at $1,825 per monthly dose across all U.S. markets, Arkansas included [1]. That figure has held steady through early 2026. A full 12-month treatment course runs $21,900 before any insurance benefit or discount program is applied.

Cash-pay prices at Arkansas retail pharmacies mirror the WAC in most cases, though some specialty pharmacies may add dispensing fees. Patients filling Evenity without insurance should request quotes from multiple pharmacies. Specialty pharmacies affiliated with major health systems in Little Rock, Fayetteville, and Fort Smith sometimes negotiate slightly lower acquisition costs than independent retailers.

Each monthly dose consists of two prefilled syringes, each containing 105 mg/1.17 mL of romosozumab-aqqg, administered as sequential subcutaneous injections [2]. The injections are given by a healthcare provider in a clinical setting, which means office visit copays or facility fees may apply on top of the drug cost itself.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months [3]. That level of fracture reduction helps contextualize the price: for patients with severe osteoporosis and prior fractures, the cost may be offset by avoided hospitalizations. A single hip fracture hospitalization in Arkansas averages $35,000 to $45,000 according to CMS data [4].

Arkansas Medicaid Coverage for Evenity

Arkansas Medicaid does cover Evenity, but access requires prior authorization. The state's preferred drug list classifies romosozumab under specialty biologics for severe osteoporosis.

To obtain approval, prescribers typically must document a T-score of <-2.5 on DXA scan, a history of osteoporotic fracture, or failure of at least one first-line therapy such as alendronate or zoledronic acid. The 2020 American Association of Clinical Endocrinology (AACE) guidelines define "very high fracture risk" as a T-score of <-2.5 with fracture history, and recommend anabolic-first sequencing with romosozumab or teriparatide in these patients [5]. Citing these criteria in the prior authorization request strengthens the case for approval.

Arkansas expanded Medicaid under the ARHOME program, which covers adults up to 138% of the federal poverty level. ARHOME beneficiaries follow the same prior authorization pathway as traditional Medicaid enrollees for specialty drugs. Processing times for PA requests in Arkansas typically run 5 to 10 business days, though urgent requests tied to imminent fracture risk can be expedited.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and lead investigator of the FRAME trial, has stated: "Romosozumab represents the first true bone-building agent that also reduces resorption simultaneously. For the highest-risk patients, starting with an anabolic agent rather than an antiresorptive changes the trajectory of their bone health" [6].

Commercial Insurance Coverage in Arkansas

Most major commercial insurers operating in Arkansas cover Evenity on their specialty tiers, though cost-sharing structures differ significantly. Blue Cross Blue Shield of Arkansas, Ambetter, QualChoice, and UnitedHealthcare all list romosozumab on their formularies with step therapy requirements.

Step therapy typically requires documented failure of, intolerance to, or contraindication for oral bisphosphonates before Evenity is approved. Some plans also require failure of denosumab (Prolia) or IV zoledronic acid. The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis recommends that patients at very high fracture risk receive initial treatment with a bone-forming agent, which can support appeals against step therapy denials [7].

Copay obligations under commercial plans range widely. Patients on preferred specialty tiers may pay $100 to $500 per month after deductible. Those on non-preferred tiers or plans with coinsurance rather than flat copays could face 20% to 30% of the drug cost, meaning $365 to $548 per injection before reaching their out-of-pocket maximum.

Patients who receive a denial should file a formal appeal. The appeal should reference AACE and Endocrine Society guidelines, the patient's fracture history, DXA results, and the ARCH trial data showing 48% vertebral fracture reduction [3]. Including a letter of medical necessity from the prescribing physician increases reversal rates.

How the Amgen/UCB Savings Card Works in Arkansas

Amgen and UCB jointly offer the Evenity Savings Card, which can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card covers up to a set annual maximum (currently $15,000 per year) in copay assistance.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Evenity, reside in the United States (Arkansas qualifies), and not be enrolled in any federal or state-funded healthcare program including Medicare, Medicaid, TRICARE, or VA benefits. The card cannot be used alongside government insurance.

Enrollment is available online through the Evenity HCP portal or by calling the Amgen support line. Once activated, the card is presented at the specialty pharmacy alongside the patient's insurance information. The pharmacy bills insurance first, then applies the savings card to the remaining copay or coinsurance balance. Processing is handled at the point of sale.

For the standard 12-dose course at $1,825 per dose, a patient with a $300 monthly copay would save $3,600 over the full treatment year through the savings card. That is a significant reduction, especially considering Arkansas's median household income of approximately $52,000 [8].

Medicare Part B Coverage in Arkansas

Medicare Part B covers Evenity when it is administered by a healthcare provider in an office or outpatient setting, which is the standard administration route. The drug falls under Medicare's "buy and bill" model.

Patients on Original Medicare pay 20% coinsurance after meeting the Part B deductible ($240 in 2025). That translates to roughly $365 per injection, or $4,380 over the full 12-month course. A Medigap supplemental plan (Plans C, F, or G are common in Arkansas) can cover part or all of that 20% coinsurance.

Medicare Advantage plans in Arkansas may impose additional utilization management requirements. Prior authorization is nearly universal across MA plans for Evenity. Some MA plans route the drug through their Part D specialty pharmacy benefit rather than Part B, which changes the cost-sharing structure. Patients should verify with their specific plan whether Evenity is covered under medical benefit (Part B) or pharmacy benefit (Part D) before starting treatment.

The FRAME trial (N=7,180) showed that romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% versus placebo at 12 months (0.5% vs. 1.8%, P<0.001) [6]. For Medicare beneficiaries with osteoporosis, who tend to be older and at higher baseline fracture risk, this magnitude of benefit is particularly relevant to coverage determinations.

Compounded Romosozumab Through 503A Pharmacies in Arkansas

Compounded romosozumab is available through licensed 503A compounding pharmacies in Arkansas. Under federal law, 503A pharmacies may compound drugs based on valid individual prescriptions when a prescriber determines it is medically appropriate for a specific patient.

The practical reality is more nuanced. Romosozumab is a monoclonal antibody produced through recombinant DNA technology. True biosimilar compounding of large-molecule biologics remains technically challenging and controversial. The FDA has repeatedly stated that 503A compounding of complex biologics raises quality and safety concerns, as compounded versions do not undergo the same immunogenicity and efficacy testing as FDA-approved products [9].

Arkansas follows federal 503A regulations without imposing additional state-level restrictions that would block compounding of specific drug categories. Patients considering this route should discuss the risk-benefit profile with their prescriber. The cost savings can be substantial (compounded versions may be priced significantly lower than the branded product), but the clinical equivalence has not been validated in controlled trials.

The AACE 2020 guidelines do not address compounded biologics specifically, but they emphasize that treatment decisions should be based on evidence from randomized controlled trials [5]. Patients with commercial insurance or Medicaid coverage for branded Evenity may find that the net cost after benefits approaches or undercuts compounded pricing once savings cards and copay assistance are factored in.

Telehealth Prescribing of Evenity in Arkansas

Arkansas permits telehealth prescribing of Evenity. A physician or qualified prescriber can evaluate a patient via telemedicine, review DXA scan results and lab work, and write a prescription for romosozumab without an in-person visit.

The prescription itself can be transmitted electronically to a specialty pharmacy for dispensing. The actual injections still require administration by a healthcare provider, so patients will need in-person visits at a clinic, infusion center, or physician's office for each monthly dose. Some home health agencies in Arkansas can administer subcutaneous injections in the patient's home, which may benefit patients in rural areas of the state with limited access to specialty clinics.

The Endocrine Society has noted that "telehealth visits are appropriate for osteoporosis management, including treatment initiation, as long as the clinician has access to the patient's imaging and laboratory data" [7]. Arkansas's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person visits, removing a potential cost barrier for the initial consultation.

Sequencing Evenity With Other Osteoporosis Drugs

Romosozumab is approved for a maximum of 12 monthly doses. Bone density gains begin to reverse after the treatment course ends unless patients transition to an antiresorptive agent.

The ARCH trial protocol transitioned patients to alendronate 70 mg weekly after completing 12 months of romosozumab [3]. This sequence produced a 50% lower incidence of new vertebral fractures and a 19% lower incidence of nonvertebral fractures compared to alendronate alone over 24 months. The trial established "anabolic first, antiresorptive second" as the preferred sequencing strategy for high-risk patients.

Denosumab (Prolia) is another common post-romosozumab option. A study published in the Journal of Bone and Mineral Research found that transitioning from romosozumab to denosumab preserved and extended bone mineral density gains at the spine and hip [10]. This sequence may be preferred for patients who cannot tolerate oral bisphosphonates.

Arkansas patients should work with their prescriber to plan the full treatment sequence before starting Evenity, including insurance pre-authorization for the follow-on antiresorptive. The cardiovascular boxed warning on Evenity's label contraindicates its use in patients who have had a myocardial infarction or stroke within the preceding year [2]. Pre-treatment cardiovascular risk assessment, including blood pressure measurement and review of cardiac history, is required.

The 2020 AACE/ACE guideline recommends: "In patients at very high fracture risk, treatment should be initiated with an osteoanabolic agent (romosozumab or teriparatide) followed by an antiresorptive to maintain gains in BMD" [5].